How Worrisome Are Heart Issues Reported With Pfizer's and Moderna's COVID Vaccines?

It's way too early to worry.



Keith Speights (TMFFishBiz)
Jun 15, 2021 at 5:54AM
Author Bio

Nearly 170 million Americans have received the COVID-19 vaccine developed by **Pfizer** (<u>NYSE:PFE</u>) and **BioNTech** (<u>NASDAQ:BNTX</u>). More than 129 million Americans have received **Moderna**'s (<u>NASDAQ:MRNA</u>) vaccine. So far, the vaccines have appeared to be both highly effective and safe.

However, the Centers for Disease Control and Prevention (CDC) is convening an "emergency meeting" of an advisory panel on June 18. The panel will discuss <u>higher-than-expected reports of heart inflammation issues</u> in young men following the second dose of the two messenger RNA (mRNA) COVID-19 vaccines. How worrisome are these heart issues reported with Pfizer's and Moderna's COVID-19 vaccines?




IMAGE SOURCE: GETTY IMAGES.

Behind the concerns

The CDC and the U.S. Food and Drug Administration (FDA) jointly run the Vaccine Adverse Event Reporting System (VAERS), which tracks reports of any side effects after individuals have received a COVID-19 vaccine. Most adverse events reported in VAERS aren't serious.

However, the CDC noticed that higher numbers of myocarditis (inflammation of the middle layer of the heart wall) and pericarditis (inflammation of the pericardium tissue that surrounds the heart) were being reported for young men than would be expected based on the number of vaccines administered. These issues were especially notable after the second dose of the mRNA vaccines.

As of May 31, 372 cases of myocarditis or pericarditis had been reported in VAERS after the second dose of the Pfizer-BioNTech vaccine. Another 201 cases of heart inflammation issues had been reported after the second dose of Moderna's vaccine. Nearly 80% of these reported cases occurred in men, with a median age of 24.

The potential issues aren't limited to the United States. Earlier this month, Israel's Health Ministry announced that there was a "probable link" between heart inflammation issues observed primarily in young men and receiving the second dose of the Pfizer-BioNTech vaccine.

Reason to worry?

The CDC hasn't established any causal link between either of the mRNA vaccines and heart inflammation issues occurring in young men at this point. Moderna issued a public statement last week that confirmed it hasn't found any causal association between its vaccine and heart inflammation "after carefully reviewing the safety data to date."

The number of heart inflammation issues reported thus far, while higher than expected, is still really low overall. The CDC specifically stated that "these reports are rare, given the number of vaccine doses administered."

It's also important to note that most individuals affected by heart

That could be what the CDC advisory panel that's scheduled to meet later this week will do after examining the available data. It's also possible that the panel will need more data before it makes any recommendations.

Minimal movement

Should investors worry about what all of this might mean for Pfizer, BioNTech, and/or Moderna? No. Most investors haven't been worried, as evidenced by the minimal movement of the <u>drug stocks</u> after the initial CDC advisory committee meeting last week where the heart inflammation issues were discussed.

Granted, it's possible that a clear link between the mRNA vaccines and heart inflammation issues in young men could be established. Even if that happens, though, the issues are rare enough that the number of doses administered of these vaccines probably wouldn't be impacted very much.

The emergence of new coronavirus strains makes it far more likely that more mRNA vaccine doses will be needed in the future. In the big scheme of things, Pfizer's and Moderna's COVID-19 vaccines are providing a lot more reasons for celebration than for concern.

Should you invest \$1,000 in Pfizer Inc. right now?

Before you consider Pfizer Inc., you'll want to hear this.

Our award-winning analyst team just revealed what they believe are the <u>10</u> <u>best stocks</u> for investors to buy right now... and Pfizer Inc. wasn't one of them.

The online investing service they've run for nearly two decades, *Motley Fool Stock Advisor*, has beaten the stock market by over 4X.* And right now, they think there are 10 stocks that are better buys.

See the 10 stocks

or Netflix when they were first recommended by the Motley Fool. I'd be sitting on a gold mine!" And it's true.

And while Amazon and Netflix have had a good run, we think these 5 **other** stocks are screaming buys. And you can buy them now for less than \$49 a share!

You can grab a copy of "5 Growth Stocks Under \$49" for FREE for a limited time only.

Click here to learn more.

Learn more